1440964-89-5

1440964-89-5 structure

Name: PLB-1001
Chemical Name: Bozitinib
CAS Number: 1440964-89-5
Molecular Formula: C₂₀H₁₅F₃N₈
Molecular Weight: 424.38
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK c-Met/HGFR
Create Date: 2019-12-10 16:52:40
Modify Date: 2024-01-13 23:04:32
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

Name	Bozitinib

Description	Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Met/HGFR
In Vitro	Bozitinib (PLB-1001) (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3, has a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways. Western Blot Analysis[1] Cell Line: Human astrocytes (HA) cells Concentration: 30 μM Incubation Time: 6 hours Result: Decreased p-STAT3,p-MET expression.
References	[1]. Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18.